[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473985":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":54,"collaborators":57,"id":61,"slug":20,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":20,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":20,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental [18F]-αvβ6-BP","EXPERIMENTAL","Patients receive \\[18F\\]-αvβ6-BP BP IV and then undergo a PET\u002FCT scan over 30 minutes 60 minutes post-injection.",[13],"Drug: [18F]-αvβ6-BP",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","[18F]-αvβ6-BP","Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Julie L. Sutcliffe, PhD","The Regents of the University of California (Davis)","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Principal Investigator","CONTACT","916-734-5536","jlsutcliffe@ucdavis.edu",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":31},"Julie L Sutcliffe","9167345536",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The University of California Davis Comprehensive Cancer Center","RECRUITING","Sacramento","California","95817","United States",{"type":44,"coordinates":45},"Point",[46,47],-121.4944,38.58157,{"lat":47,"lon":46},[50,51],{"name":33,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":52,"role":53,"phone":20,"phoneExt":20,"email":20},"Megan Daly, MD","SUB_INVESTIGATOR",{"type":25,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Julie L. Sutcliffe, Ph.D","Professor of Internal Medicine and Biomedical Engineering",[58],{"name":59,"class":60},"United States Department of Defense","FED","100473985",false,"NCT05452005","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Men and women age \\>18 yrs\n2. Biopsy proven NSCLC with brain metastases (treated or untreated)\n3. Life-expectancy of ≥3 months in the opinion of the treating physician\n4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.\n5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan\n6. Ability to understand and willingness to sign a written informed consent document.\n7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging\n8. \\[18F\\]-FDG PET\u002FCT within 21 days of enrollment\n9. MRI brain within 21 days of enrollment\n10. Eastern Cooperative Oncology Group Performance Status ≤ 2\n11. Glomerular filtration rate (GFR) ≥ 60\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Prisoners\n3. Concurrent malignancy of a different histology that could confound imaging interpretation\n4. Patients who cannot undergo PET\u002FCT scanning because of weight limits(\\>350lbs)","ALL","18 Years",{"count":70,"type":71},20,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This study investigates fluorine-18-AlphaVBeta6-BP (\\[18F\\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \\[18F\\]-αvβ6-BP PET\u002FComputed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.",[77,78,79,80],"Lung Cancer","Lung Cancer Metastatic","Brain Metastases","Non Small Cell Lung Cancer",[82],"Positron Emission Tomography","2026-02-23",{"date":85,"type":86},"2026-02-27","ACTUAL",{"date":88,"type":86},"2022-09-13",{"date":90,"type":71},"2026-12-31",{"name":5,"class":6},1]